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METHODOLOGY Open Access
Developing clinical practice guidelines: reviewing,
reporting, and publishing guidelines; updating
guidelines; and the emerging issues of enhancing
guideline implementability and accounting for
comorbid conditions in guideline development
Paul Shekelle1,2*, Steven Woolf3, Jeremy M Grimshaw4,5, Holger J Schünemann6 and Martin P Eccles7
Abstract
Clinical practice guidelines are one of the foundations of efforts to improve health care. In 1999, we authored a
paper about methods to develop guidelines. Since it was published, the methods of guideline development have
progressed both in terms of methods and necessary procedures and the context for guideline development has
changed with the emergence of guideline clearing houses and large scale guideline production organisations (such
as the UK National Institute for Health and Clinical Excellence). It therefore seems timely to, in a series of three
articles, update and extend our earlier paper. In this third paper we discuss the issues of: reviewing, reporting, and
publishing guidelines; updating guidelines; and the two emerging issues of enhancing guideline implementability
and how guideline developers should approach dealing with the issue of patients who will be the subject of
guidelines having co-morbid conditions.
Background
Clinical practice guidelines (hereafter referred to as
guidelines) are one of the foundations for efforts to im-
prove health care. The modern age of guidelines began
with a 1992 IOM report, which defined guidelines as
“systematically developed statements to assist practi-
tioner and patient decisions about appropriate health
care for specific clinical circumstances” [1]. In 1999, we
authored a paper about methods to develop guidelines
[2]. It covered: Identifying and refining the subject area
of the guideline; Running guideline development groups;
Identifying and assessing the evidence; Translating evi-
dence into a clinical practice guideline; and Reviewing
and updating guidelines. Since it was published, the
methods of guideline development have progressed both
in terms of methods and necessary procedures and the
broad context for clinical practice guidelines has changed.
To help users identify and choose guidelines there has
been the emergence of guideline clearing houses (such as
the AHRQ Guideline Clearing House (www.guideline.gov))
that identify and systematically characterize guidelines on a
number of domains and the development of robust guide-
line appraisal instruments such as the AGREE tool [3,4].
There has been the appearance of large scale guideline pro-
duction organisations both at a national level (such as the
UK National Institute for Health and Clinical Excellence or
Scottish Intercollegiate Guidelines Network) and a condi-
tion level (such as the Ontario Cancer Guideline Program).
There have also been relevant reports (that some of us have
participated in) for the World Health Organisation [5] and
professional societies (Schünemann HJ, Woodhead M,
Anzueto A, Buist AS, MacNee W, Rabe KF, Heffner J. A
guide for guidelines for professional societies and other
developers of recommendations: an official American
Thoracic Society (ATS)/European Respiratory Society
(ERS) Workshop Report; forthcoming). Such organizations
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and those interested in producing and using guidelines now
have a high profile society in the Guidelines International
Network (http://www.g-i-n.net/). Against this background
it seems timely to, in a series of three articles, update and
extend our earlier paper on the methods of developing clin-
ical practice guidelines. This series is based on a back-
ground paper [6] we prepared for the Institute of Medicine
report “Clinical Practice Guidelines We Can Trust” [7].
In the first paper we discussed target audience(s) for
guidelines, identifying topics for guidelines, guideline
group composition and the processes by which guideline
groups function and the important procedural issue of
conflicts of interest. In the second paper we discussed
issues of identifying and synthesizing evidence: deciding
what type of evidence and outcomes to include in guide-
lines; integrating values into a guideline; incorporating
economic considerations; synthesis, grading, presenta-
tion of evidence; and moving from evidence to recom-
mendations. In this third and final paper in the series we
discuss the issues of: reviewing, reporting, and publish-
ing guidelines; updating guidelines; and two emerging
issues - enhancing guideline implementability and how
guideline developers should approach dealing with the
issue of patients who will be the subject of guidelines
having co-morbid conditions.
Reviewing, reporting, and publishing guidelines
Peer review and consultation
Only so many experts and perspectives can be repre-
sented on a guideline group. The review process pro-
vides an opportunity to elicit input from broader and
important perspectives that the group itself cannot en-
compass but that have important insights into the
evidence (and its contestability) or the challenges of
adopting recommendations. This can be divided into the
two steps of invited peer review, where the reviewers are
identified by the guideline developers on the basis of
their perceived ability to contribute, and public consult-
ation, where the document is open to comment from
any interested party.
Invited peer review
The means by which review comments are solicited is
typically by mailing draft documents to the reviewers
along with instructions on relevant criteria and a dead-
line for feedback. However, some groups obtain similar
input and criticism earlier in the process by forming ad-
visory groups that include some of the above stake-
holders. The advisory group may not have voting power
but may receive draft documents, correspondence, and
updates as the guideline group deliberates. The group’s
meetings can also be attended by observers who repre-
sent the above interest groups, or they may be invited to
an open forum, hearing, or workshop to present papers
and testimonials to the guideline group. These observers
may share criticisms in person at such meetings or for-
ward concerns offline in correspondence with the group
or its organizational/agency sponsor. As an endeavor in
scholarship, documents and recommendations devel-
oped by a guideline group should be critically reviewed
by colleagues and experts to identify errors and omis-
sions, suggestions for improvement and clarification,
and debate about the rationale. The criticism is helpful
in four ways (Table 1).
Reviewers with expertise on relevant past research and
studies in progress and mastery of the clinical topic can
identify relevant studies that were overlooked, mistakes
made in describing studies or their results, flaws in
commentaries about the quality of the studies, methodo-
logical and statistical errors in pooling data in meta-
analyses or models, and imbalance and asymmetry in
presenting the evidence. Reviewers can challenge the
logic used by the guideline group in translating the evi-
dence into recommendations. They can note, for ex-
ample, when the evidence presented does not support
the recommendation offered and call attention to biases,
political pressure, or other factors that may be coloring
the group’s judgments. Reviewers with knowledge of the
realities of clinical practice and the administration of
health systems can provide useful feedback on how eas-
ily the recommendations can be adopted, or even under-
stood, by clinicians and systems of care. Language issues
that create ambiguities in explicating which patients are
affected and the details of the intervention can be identi-
fied. Reviewers grounded in the “real world” can also
identify broader policy ramifications, such as the lack of
providers or technology to support a recommendation,
implications for reimbursement or medico-legal liability,
impracticalities created for information systems or per-
formance review criteria, upcoming legislation or pol-
icies that bear on the topic, and political resistance the
recommendations will face.
The group’s procedures for selecting reviewers should
pay attention to this consideration in choosing poten-
tially harsh critics who can articulate their scientific or
clinical reasoning. It should also take note of the need to
be explicit about conflicts of interest (as discussed in the
first paper in this series). Inviting criticism from provider
groups and specialty societies who are expected to be
critical is also important.
Table 1 Advantages of external review of a guideline
(1) Checking the accuracy, comprehensiveness, and balance of the
scientific evidence
(2) Checking the validity of the rationale for recommendations
(3) Feedback on the clarity and feasibility of recommendations
(4) Engagement of stakeholders
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Public consultation
It is prudent to share drafts with a spectrum of reviewers
who include not only supporters but also the individuals,
specialty groups, and industries expected to be critical of
the group’s characterization of the evidence or of their
recommendations. Reviewers can be given clear instruc-
tions to accompany their criticisms with relevant scien-
tific evidence and citations to support their criticisms
and suggestions. Reviewers who express strong views
but cannot present a cogent scientific rationale may be
less helpful than critics who can articulate a sound sci-
entific and clinical argument for their views.
Whether or not their feedback is useful on substance,
inviting comments and criticism from stakeholders is
important for “buy-in” to give the major players a sense
of partnership in the process rather than feeling
excluded. Thus, even if scientific and clinical review is
already provided by leading experts, comments are often
invited from relevant specialty societies (e.g., American
Academy of Pediatrics), disease-related organizations
(e.g., American Diabetes Association), government agen-
cies (e.g., Centers for Disease Control), and other bodies
that are relevant to the topic in question. Perhaps the
most useful benefit of review by stakeholders lies in poten-
tially engaging their assistance in promoting awareness
and adoption of the recommendations when they are
released. Specialty societies and other entities that have
played a role in reviewing and improving guidelines are
often willing to participate in an outreach effort to pro-
mote its implementation.
Dealing with peer review
Inviting criticism of draft documents hardly guarantees
that the final guideline will escape criticism. In particu-
lar, critics of guidelines can fault the review process if
there is a perception that their criticisms were submitted
but ignored. Therefore, it is useful for the guideline
group to adopt an open, systematic and fair process for
receiving and responding to review comments. For ex-
ample, the group can maintain a database in which it
documents every criticism or comment it receives from
every reviewer, how the guideline was or was not modi-
fied, and the rationale for actions taken or for inaction.
Making such a document available to the public is im-
portant for transparency, and some groups even post it
on their website.
How groups react to review comments is, or ideally
should be, consistent with the methodology it used in
making the original recommendations. For example, if a
group accepted expert opinion as a determinant of recom-
mendations, criticism by experts that the recommendation
is inappropriate or public or political disfavor might be rea-
son enough for rewording the recommendation. Con-
versely, on the other extreme, if a group’s methodology
insists on evidence from well-designed randomized con-
trolled trials, neither strident expert opinions nor a lengthy
bibliography of supporting cohort studies are necessarily
grounds for revising the recommendations. The harshest
criticism from a topic expert or organization might merit
no action if the reviewer cannot produce evidence or ra-
tionale that is relevant to the group’s methodology for mak-
ing recommendations. The group must hold an explicit
methodology with explicit rules of evidence and criteria for
recommendations, however, to justifiably invoke the latter
as an excuse for ignoring criticisms.
Peer-reviewed publications
Publishing practice guidelines (or the evidence reviews
on which they are based) in a peer-reviewed publication
offers an additional opportunity for critical appraisal by
anonymous reviewers and feedback to improve the guide-
lines. Publication in a peer-reviewed journal also enhances
the scientific credentials of the guideline and act as a
“stamp of approval,” which can be important to some
clinicians, patients, academia, and policymakers. For
guideline groups and sponsoring organizations that
lack the resources to widely publicize or disseminate
guidelines on their own, journal publication provides
a venue for distributing print copies and, increasingly,
an online platform for full-text retrieval of electronic
copies of the guidelines, evidence reviews, data tables,
and other supplementary information.
Submitting guidelines for publication in a peer-
reviewed journal is not without its disadvantages, how-
ever. First, the peer-review process, the need to revise
and resubmit the guidelines, and rejections that require
submission to other journals are time-consuming steps
that can introduce lengthy delays in the release of guide-
lines. Once accepted, journals may require additional
time for production of the issue and exercise partial or
exclusive control over the timing of the release. A guide-
line may be published a year or more after its comple-
tion by the group, long after the publication date of the
most recent studies reviewed by the group. By then, new
studies or new interventions may make the guideline ob-
solete or at least dated. Second, editors may insist on
modifications to the guideline or evidence review that
are responsive to the comments of their reviewers but
that change documents and language that the guideline
group has carefully crafted, often in response to exten-
sive review by leading authorities. The wording and
structure recommended by this extensive process may
run up against the recommendations of a handful of
reviewers selected by the journal as part of its ordinary
peer review process. Some journals address this problem
by accepting a group’s review process in lieu of the jour-
nal’s normal review procedures. Third, either because of
the above difficulties or the style and formatting policies
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of the journal, the peer-reviewed version may differ from
other versions released by the guideline group or its
sponsoring organization or agency, creating troubling
inconsistencies.
Other publications
Guideline groups now often develop multiple products
to cater to a multiplicity of target audiences. For ex-
ample, a short guideline summary may be intended for
busy clinicians or policymakers whose interest lies only
in knowing the core recommendation and not the
underlying evidence or the group’s rationale. A technical
report, which may include detailed evidence reviews, evi-
dence summary tables, and modeling results, may be
produced for audiences interested in studying the sci-
ence and critiquing the quality of the scientific reason-
ing. A lay version of the guideline may be produced to
explain the aspects of the guideline that are relevant to
patients, often using language that is free of technical
jargon and is accompanied by useful graphics or illustra-
tions. The above documents are typically disseminated
in an electronic format, as HTML or PDF documents
accessible online, but some guidelines may also include
a print publication in a peer-reviewed medical journal,
to reach audiences who prefer print media or view the
latter as an important metric for scientific credibility.
Two decades ago, whether as peer-reviewed or other
publications, guidelines and related products (e.g., evi-
dence reviews, data tables, modeling studies, patient
education materials) were almost exclusively print publi-
cations that arrived in the mail and sat on shelves and
desks. In the modern era, although print publications re-
main a staple, an increasing proportion of publications
are available and more widely used electronically in
searchable online HTML and PDF formats. Increasingly,
guidelines are being provided with interactive “front
ends” that allow users to navigate or interrogate the
guideline or supporting evidence. Some guidelines or
supporting materials are available for full-text retrieval
at no charge and are therefore more accessible to the
general public, whereas others require some payment for
controlled access. Guidelines sometimes spawn related
decision support tools or software to implement the
guideline in practice.
Updating guidelines
It is well recognized that guidelines become out of
date and therefore require updating. We have previ-
ously argued that there were six situations (Table 2)
that might necessitate the updating of a clinical prac-
tice guideline [8]. Changes in the values placed on
outcomes often reflect societal norms. Measuring the
values placed on outcomes and how these change
over time is complex and has not been systematically
studied. When changes occur in the availability of
resources for health care or the costs of interventions,
a generic policy on updating is unlikely to be helpful,
because policy makers in disparate health care sys-
tems consider different factors in deciding whether
services remain affordable. Most effort has been
directed towards defining when new information on
interventions, outcomes and performance justifies up-
dating guidelines. This process includes two stages: 1)
identifying significant new evidence, and 2) assessing
whether the new evidence warrants updating. Within any
individual guideline it is possible that there will be some
recommendations that are invalid whilst others remain
current. A guideline on congestive heart failure [9] for ex-
ample, includes 37 individual recommendations. How
many must be invalid to require updating the whole
guideline? Clearly a guideline needs updating if the major-
ity of recommendations are out-of-date, with new evi-
dence demonstrating that the recommended interventions
are inappropriate, ineffective, or superseded by new inter-
ventions. In other cases a single, outdated recommenda-
tion could invalidate the entire document. Judgments
about whether a guideline needs updating are inherently
subjective and reflect the clinical importance and number
of invalid recommendations. Shekelle and colleagues
described an operational method based on their concep-
tual model, presented above, in relation to the need for
updating of 17 clinical guidelines published by the Agency
for Healthcare Research and Quality [10]. They found that
seven guidelines were so far out of date that a major up-
date was required, an additional six guidelines required a
minor update, three guidelines were still valid, and for one
guideline they could reach no conclusion. They concluded
that as a general rule, guidelines should be re-evaluated
no less frequently than every three years. In an evaluation
of the need for updating systematic reviews, Shojania and
colleagues found that almost one quarter of systematic
reviews are likely out-of-date at two years post-publication
[11]. This method provided a way of balancing the
resources required for updating with the potential benefits
assuming that a full re-development of a guideline on each
occasion was not necessarily an efficient use of resources.
Gartlerhner and colleagues [12] explicitly addressed this
Table 2 Situations that might necessitate the updating of
a clinical practice guideline
1. Changes in the evidence on the existing benefits and harms of
interventions:
2. Changes in the outcomes considered important:
3. Changes in the available interventions:
4. Changes in the evidence that current practice is optimal:
5. Changes in the values placed on outcomes:
6. Changes in the resources available for health care:
Shekelle et al. Implementation Science 2012, 7:62 Page 4 of 7
http://www.implementationscience.com/content/7/1/62
issue when they compared this method (which they termed
the review method) with a “traditional” method of updating
(comparable to de novo guideline development) across six
topics from the 1996 US Preventive Services Taskforce
Guide to Clinical Preventive Services in terms of the com-
pleteness of study identification, the importance of any
studies that were missed by either method and the ef-
fort involved in the methods. Their results showed
that “Although the review approach identified fewer
eligible studies than the traditional approach, none of
the studies missed was rated as important by task
force members acting as liaisons to the project with
respect to whether the topic required an update. On
average, the review approach produced substantially fewer
citations to review than the traditional approach. The effort
involved and potential time saving depended largely on the
scope of the topic”. On the basis of this they concluded that
“The revised review approach provides an efficient and ac-
ceptable method for judging whether a guideline requires
updating”.
A description of updating in a cancer guidance pro-
gram [13] concluded that for their purposes that a more
frequent, three monthly, literature search was needed
though they found that the productiveness of this varied
across different guidelines.
These issues have been enshrined within the pro-
cesses of some guideline development programs and
in the UK the National Institute for Health and Clinical
Excellence (NICE) recommends a combination of literature
searching and professional opinion to inform the need for a
“full” or “partial” updates and describes its processes
for these - though they involve both changes in the
evidence relating to a guideline and extensions of the
scope of a guideline (changes in the outcomes consid-
ered important or available interventions). The assess-
ment of the need for an update happens every three
years. In the National Guideline Clearinghouse, guide-
lines are required to have been re-examined every
three years.
Emerging issues
There are two emerging issues around which there is
considerably less evidence or experience to guide guide-
line developers - what guideline developers can do to
enhance guideline implementability and how guideline
developers should deal with the fact that, despite guide-
lines addressing single condition guidelines, many
patients do not just have single clinical conditions.
Strategies to promote the implementation of guidelines are
beyond the scope of this paper but the interested reader is
directed to the work of the Cochrane Collaboration
Effective Practice and Organisation of Care Review Group
in the Cochrane Library (www.thecochranelibrary.com).
Enhancing guideline implementability
Guidelines are not self implementing. Developing guide-
lines and making them available to health care profes-
sionals does not ensure their use. Whilst guideline
developers may have some responsibility for guideline dis-
semination they rarely have responsibility for guideline
implementation. Guideline dissemination is sometimes
undertaken by the developer and sometimes undertaken
by practitioners or managers of the health care system or
professional societies or the pharmaceutical industry. By
contrast, guideline implementation is usually the responsi-
bility of practitioners or managers. As a result, it is not al-
ways clear what role guideline developers should have in
dissemination and implementation.
There are studies that suggest that the specificity of
guideline recommendations affects their use [14] and
observational studies that suggest that attributes of
recommendations affect clinicians report of how they
would use them [15]. There is also an instrument for
assessing implementability [16] and a recent article has
proposed an implementability framework [17]. The pro-
posed implementablity framework (Table 3) was devel-
oped by the authors and then tested against a number of
guidelines. They reported that many of the guidelines
did not include features that (even on current limited
knowledge) are known to promote guideline use. How-
ever, they also acknowledge that it is an empirical ques-
tion as to whether including such information increases
guideline use. Apart from studies such as these, there is
relatively little research evidence about how guideline
developers should improve implementability but there
are a number of ongoing studies that should provide
guidance for developers in the next few years. If guide-
line developers wish to enhance the implementability of
their guidelines then current best practice suggests that
developers should develop formal relationships with
those in health care systems responsible for guideline
dissemination and implementation and then use
Table 3 Strategies to support guideline uptake
• Pre-emptive identification of potential barriers of recommendations,
and a priori generation of solutions to address them by the guideline
development group. At a minimum the guideline group should be
aware of the potential barriers;
• Use of behaviorally specific language in the guideline [18], [19], [14];
• Use of multiple formats and channels for guideline dissemination
based on preferences of the target group of health care practitioners;
• Development of educational resources adapted in content, and vehicle
to each target group of health care practitioners;
• Identification of the resource implications of recommendations,
ensuring their availability before starting;
• Use of data collection tools (for example, simple audit templates).
From: Gagliardi et al. How can we improve guideline use? A conceptual
framework of implementability. Implementation Science 2011, 6:26.
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strategies to support guideline uptake such as those in
Table 3.
Accounting for comorbidities when developing
guidelines
An emerging topic of interest when developing practice
guidelines is how to shape guideline development to ac-
count for patients who have multiple medical conditions.
This issue was highlighted by Boyd and colleagues, who
assessed the applicability of guidelines to a hypothetical
79 year old woman with five chronic conditions: osteopor-
osis, osteoarthritis, diabetes, hypertension, and chronic
obstructive pulmonary disease [20]. Boyd and colleagues
noted that guidelines for these conditions, with the excep-
tion of diabetes, did not discuss recommendations for
management in patients with other chronic conditions.
Applying the guidelines to their hypothetical patient, they
found the patient would need to be advised of seven self-
management tasks, the clinician would be responsible for
performing 18 tasks, the patient would be recommended
to take 12 separate medications in 19 doses per day, and
that certain medications recommended for one condition
could exacerbate symptoms or interact with medications
for other conditions (e.g., NSAIDs for osteoarthritis po-
tentially raising the blood pressure in hypertension; hydro-
chlorothiazide for hypertension potentially raising glucose
levels in diabetes). Boyd and colleagues concluded that
attempting to apply current guidelines to patients with
multiple health conditions may have undesirable effects.
It is perhaps not surprising that guidelines have
remained largely silent about what to do when patients
have multiple conditions and that there has been little
progress in rectifying this situation. Clinical practice
guidelines aspire to be evidence-based, and often the
studies used as the evidentiary base have excluded
patients with multiple chronic conditions. Consequently,
there rarely are data about the effect that the presence
of other health conditions have on the treatments and
outcomes of care for a particular condition - knowledge
that would translate into differences in treatment recom-
mendations in a guideline depending on the presence of
certain other chronic conditions. The exception to this
general rule is diabetes, where there are data about dif-
ferences in outcomes for patients with hypertension and
with cardiovascular disease, in terms of optimal blood
pressure control and LDL levels, and these data have
been translated into differential treatment recommenda-
tions in practice guidelines. Having epidemiologic data
on the frequency of co-morbidities with the target condi-
tion would inform the discussion regarding the presence
or absence of evidence about how these comorbidities
should or should not influence treatment decisions. In the
context of diabetes, Piette and Kerr have articulated the
concept of “concordant” versus “discordant” comorbidities,
with “concordant” comorbidities being ones that tend to
have similar management plans (for example, the triad of
hypertension, diabetes and coronary artery disease) while
discordant comorbidities do not have the feature and do
not share any underlying predisposing factor (diabetes and
asthma or diabetes and prostate cancer) [21]. This concept
may be useful to guideline development committees when
thinking about dealing with recommendations for patients
with co-morbidities. Likewise, Boyd and colleagues have
developed a framework for thinking about disease severity
in older adults, which includes the effect of the interaction
of disease severity on other diseases [22]. Since treating
one condition optimally (such as use of increased doses of
non-steroidal anti-inflammatory drugs for osteoarthritis)
may cause an increased risk of side effects (gastrointestinal
bleeding) that can be mitigated by adding another medica-
tion (proton pump inhibitors) that unfortunately has a pos-
sible deleterious action on the outcomes of another health
condition (the use of clopidogrel in patients who have had
coronary artery revascularization interventions), weighing
the risks and benefits of treatments across a patient’s health
conditions will be necessary, and will likely involve a discus-
sion with the patient about preferences for outcomes.
Methods to incorporate individual patient values is an ac-
tive area of research [23]. From the clinical area of respira-
tory disease practical guidance will be forthcoming (Fabbri
LF, BoydC, Boschetto P, Rabe KF, Buist AS, Yawn B, Leff B,
Kent DM, Schünemann HJ. How to integrate multiple
comorbidities in guideline development: An official ATS/
ERS Workshop Report. Forthcoming).
Summary
In this third and final paper in the series we discussed
the issues around: reviewing, reporting, and publishing
guidelines; updating guidelines, and the emerging issues
of enhancing implementability and how guidelines ap-
proach dealing with patients with co-morbid conditions.
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